Float Short %

8.65

Margin Of Safety %

Put/Call OI Ratio

0.02

EPS Next Q Diff

0.24

EPS Last/This Y

0.63

EPS This/Next Y

1.28

Price

0.54

Target Price

1.07

Analyst Recom

2.71

Performance Q

-70.01

Relative Volume

0.39

Beta

1.03

Ticker: MRNS

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	MRNS	0.24	0.03	1.00	8031
2024-12-20	MRNS	0.2387	0.03	0.18	8033
2024-12-23	MRNS	0.2318	0.03	0.00	7301
2024-12-24	MRNS	0.2572	0.03	0.00	7311
2024-12-26	MRNS	0.3279	0.03	0.08	7315
2024-12-27	MRNS	0.379	0.03	0.00	7339
2024-12-30	MRNS	0.53	0.03	0.01	8521
2024-12-31	MRNS	0.5329	0.03	0.01	14341
2025-01-02	MRNS	0.5287	0.02	0.04	14692
2025-01-03	MRNS	0.536	0.02	0.01	14840
2025-01-06	MRNS	0.5365	0.02	0.00	14797
2025-01-07	MRNS	0.5321	0.02	0.00	15129
2025-01-08	MRNS	0.532	0.02	0.00	15264
2025-01-09	MRNS	0.532	0.02	0.00	15264
2025-01-10	MRNS	0.537	0.02	0.00	15234
2025-01-13	MRNS	0.5422	0.02	0.02	15280
2025-01-14	MRNS	0.5394	0.02	0.00	15291
2025-01-15	MRNS	0.542	0.02	0.00	15291
2025-01-16	MRNS	0.543	0.02	0.00	15282
2025-01-17	MRNS	0.541	0.02	0.01	15281
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	MRNS	0.24	64.7	-	-2.00
2024-12-20	MRNS	0.24	64.7	-	-2.00
2024-12-23	MRNS	0.24	64.7	-	-2.00
2024-12-24	MRNS	0.26	64.7	-	-2.00
2024-12-26	MRNS	0.32	64.7	-	-2.00
2024-12-27	MRNS	0.38	64.7	-	-2.00
2024-12-30	MRNS	0.53	64.7	-	-2.00
2024-12-31	MRNS	0.54	64.7	-	-2.00
2025-01-02	MRNS	0.53	64.7	-	-2.00
2025-01-03	MRNS	0.54	64.7	-	-2.00
2025-01-06	MRNS	0.53	64.7	-	-2.00
2025-01-07	MRNS	0.53	64.7	-	-2.00
2025-01-08	MRNS	0.53	64.7	-	-2.00
2025-01-09	MRNS	0.53	64.7	-	-2.00
2025-01-10	MRNS	0.54	64.7	-	-2.00
2025-01-13	MRNS	0.54	64.7	-	-2.00
2025-01-14	MRNS	0.54	64.7	-	-2.00
2025-01-15	MRNS	0.54	64.7	-	-2.00
2025-01-16	MRNS	0.54	64.7	-	-2.00
2025-01-17	MRNS	0.54	64.7	-	-2.00
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	MRNS	-0.22	-16.13	10.46
2024-12-20	MRNS	-0.22	-16.13	10.46
2024-12-23	MRNS	-0.23	-16.13	10.46
2024-12-24	MRNS	-0.23	-16.13	10.46
2024-12-26	MRNS	-0.20	-16.13	10.30
2024-12-27	MRNS	-0.22	-16.13	10.30
2024-12-30	MRNS	-0.19	-16.17	10.30
2024-12-31	MRNS	-0.19	-16.17	10.30
2025-01-02	MRNS	-0.21	-16.17	10.30
2025-01-03	MRNS	-0.22	-16.17	10.30
2025-01-06	MRNS	-0.22	-16.31	10.30
2025-01-07	MRNS	-0.22	-16.31	10.30
2025-01-08	MRNS	-0.22	-16.31	10.30
2025-01-09	MRNS	-0.22	-16.31	10.30
2025-01-10	MRNS	-0.22	-16.31	10.30
2025-01-13	MRNS	-0.22	-16.31	8.65
2025-01-14	MRNS	-0.22	-16.31	8.65
2025-01-15	MRNS	-0.22	-16.31	8.65
2025-01-16	MRNS	-0.22	-16.31	8.65
2025-01-17	MRNS	-0.22	-16.31	8.65
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.42

Avg. EPS Est. Current Quarter

-0.28

Avg. EPS Est. Next Quarter

-0.18

Insider Transactions

-0.22

Institutional Transactions

-16.31

Beta

1.03

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.3

Max Drawdown 5-Year %

-98.8

Target Price

1.07

P/E

Forward P/E

PEG

P/S

0.95

P/B

P/Free Cash Flow

EPS

-2.47

Average EPS Est. Cur. Y

-2

EPS Next Y. (Est.)

-0.72

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-446.49

Relative Volume

0.39

Return on Equity vs Sector %

191.4

Return on Equity vs Industry %

204

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.14

EBIT Estimation

Marinus Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 165

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

stock quote shares MRNS – Marinus Pharmaceuticals, Inc. Stock Price stock today

news today MRNS – Marinus Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MRNS – Marinus Pharmaceuticals, Inc. yahoo finance google finance

stock history MRNS – Marinus Pharmaceuticals, Inc. invest stock market

stock prices MRNS premarket after hours

ticker MRNS fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MRNS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y